Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.64 - $3.3 $91,676 - $184,470
-55,900 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$2.13 - $3.24 $213 - $324
100 Added 0.18%
55,900 $161,000
Q4 2021

Feb 14, 2022

SELL
$2.85 - $6.58 $16,815 - $38,822
-5,900 Reduced 9.56%
55,800 $170,000
Q1 2021

May 06, 2021

SELL
$9.38 - $13.63 $30,954 - $44,979
-3,300 Reduced 5.08%
61,700 $600,000
Q3 2020

Nov 12, 2020

SELL
$9.5 - $11.14 $84,550 - $99,146
-8,900 Reduced 12.04%
65,000 $656,000
Q2 2020

Aug 13, 2020

SELL
$7.01 - $13.24 $46,266 - $87,384
-6,600 Reduced 8.2%
73,900 $771,000
Q3 2019

Nov 14, 2019

BUY
$8.75 - $12.85 $80,500 - $118,220
9,200 Added 12.9%
80,500 $867,000
Q2 2019

Aug 14, 2019

BUY
$12.3 - $35.76 $314,880 - $915,456
25,600 Added 56.02%
71,300 $906,000
Q4 2018

Feb 13, 2019

SELL
$20.07 - $46.7 $2.52 Million - $5.87 Million
-125,640 Reduced 73.33%
45,700 $930,000
Q3 2018

Nov 08, 2018

BUY
$41.2 - $59.85 $5.29 Million - $7.68 Million
128,300 Added 298.09%
171,340 $7.86 Million
Q2 2018

Aug 13, 2018

SELL
$48.3 - $68.25 $1.2 Million - $1.7 Million
-24,860 Reduced 36.61%
43,040 $2.55 Million
Q1 2018

May 14, 2018

BUY
$59.7 - $99.25 $425,661 - $707,652
7,130 Added 11.73%
67,900 $4.62 Million
Q4 2017

Feb 13, 2018

SELL
$93.85 - $132.45 $471,127 - $664,899
-5,020 Reduced 7.63%
60,770 $6.01 Million
Q3 2017

Nov 13, 2017

BUY
$72.0 - $119.75 $4.74 Million - $7.88 Million
65,790
65,790 $7.88 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $134M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.